Ekf Diagnostics Share Discussion Threads

[wan] 30/7/2022 08:37

To reaffirm my commentary above -

Core diagnostic growth offsets falling COVID-19 sales at Hologic, Thermo Fisher and Qiagen

Rising demand for core diagnostics offset better-than-feared declines in COVID-19 test sales, shedding light on the companies’ post-pandemic futures.

Published July 29, 2022

Hologic, Thermo Fisher Scientific and Qiagen reported quarterly financial results this week, revealing how rising demand for core diagnostics has offset better-than-feared falls in COVID-19 test sales. Here, we look at the key takeaways from each set of results.

Full article -

Readers will note the final paragraphs from Qiagen regarding their energy use in Germany, and from what I can tell electricity is EKF's main source of energy use too. Not to mention that healthcare related products are regarded as being critical and therefore it's a sector that gets prioritisation -

Planning for disruption
After measures like this have been exhausted, EU countries “may need to start curtailing partially or fully specific consumer groups” identified in the “emergency” stage of their national crisis plans.

Prioritisation of sectors is likely to differ between EU countries, but “it is advisable, to include the impact on health, food, safety and environment, security, and defence in their national prioritisation,” the leaked document says.

The demand reduction plan gives guidance to governments on how to determine which sectors to prioritise, with four considerations:

> “Societal criticality”: how important the sector or product is to society, particularly when it comes to health, safety, environment and security.

> “Cross-border supply chains”: to what extent the product is part of cross-border supply chains and would disrupt the smooth provision of essential societal services at the EU level.

>“Substitution and reduction possibilities”: whether fossil gas can be replaced or energy savings measures can be used.

> “Damage to installations”: what damage could be caused to industrial tools in the case of a temporary shut down and the cost of repair. This particularly looks at sectors that need to run continuously, like parts of the medical industry, pharmaceuticals, chemical processes, glass and steel.

One way of prioritising could be to look at the product level, rather than the sector. For instance, not all glass production would be prioritised, but glass for food containers, vials and syringes and renewable infrastructure might be, the document suggests.

Source Euractiv. Full article -

[wan] 29/7/2022 12:41

Large diagnostic companies continued their reporting in the US yesterday. Covid testing aside, core revenues rose. Thermo Fisher and Hologic being the standouts with both reporting mid double digit revenue growth, well above analysts' estimates, and both companies announcing an increase in full-year revenue guidance.

In my view, this is how I expect healthcare, in particular diagnostics, to perform, as they can still perform and grow even in a turbulent/challenging market environment given their solid installed bases and resulting recurring revenues.

Staying with diagnostics, a new EKF buffer formulation now looks imminent(and a topic that I was perhaps previously too premature in covering during the early stages of the pandemic) -

28th July 2022
Our amazing Development Scientist Francesca Cole is supervising the second Contract Buffer Formulation event for a new contract manufacturing customer, taking place in the Production Feasibility Lab in Cardiff.
👀 Keep an eye out next week when this product will be dispensed into tubes

[tongosti] 29/7/2022 10:15

Over the last few weeks one has seen definitive signs of accumulation. A break north of 39 would finally confirm the trend has reversed.

[tongosti] 28/7/2022 10:49

Very constructive price action over the last few days. First time (since Nov 21) where we see several days north of 50 dma.

[tongosti] 26/7/2022 11:30

As soon as our ramper reappeared the tentative advance came to a screeching halt.

[wan] 23/7/2022 09:28

Interesting comment given that another division of Octopus recently sold shares in EKF, but I appreciate the remit/investment criteria between divisions is probably different -

Friday 22 July, 2022
Octopus AIM VCT 2 plc
Half-Yearly Results

EKF Diagnostics and Gear4Music have both suffered from a re-calibration of profit forecasts after exceptional profits were made during the pandemic. However, underlying growth remains good and is not reflected in the current valuation.

[wan] 22/7/2022 07:53

Large diagnostic companies have started their quarterly reporting in the US. So far
core business revenue growth is the range of down slightly to mid-single digit growth, despite headwinds from COVID 19-related shutdowns in China, and with healthcare/diagnostics providing resilience in the face of any economic slowdown or recession.

Their forecasts for the full year being either broadly maintained, or increased in the low-single digit to high-single digit percent range. In this regard, Danaher was the standout, who's shares rose approximately 8 percent yesterday.

M&A is still very much part of Quest Diagnostics growth strategy.

In other news, Amazon made a large move in the healthcare sector, announcing its plans to acquire One Medical for $3.9 billion -

SEATTLE & SAN FRANCISCO—(BUSINESS WIRE)—July 21, 2022—Today Amazon (NASDAQ:AMZN) and One Medical (NASDAQ:ONEM) announced that they have entered into a definitive merger agreement under which Amazon will acquire One Medical. One Medical is a human-centered, technology-powered national primary care organization on a mission to make quality care more affordable, accessible, and enjoyable through a seamless combination of in-person, digital, and virtual care services that are convenient to where people work, shop, and live.
Full release -

[tongosti] 21/7/2022 10:25

Don't jinx it wan. This share was already tempting a comeback in the absence of daily ramping. Lol

[wan] 21/7/2022 08:12

Worthy of note -

PURISSIMA ANNOUNCES MULTI-YEAR PROCESSING AND DISTRIBUTION PARTNERSHIP WITH OPEN BOOK EXTRACTS
NEWS PROVIDED BY Purissima
Jul 19, 2022

SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Purissima, a leading, next-generation, biotechnology health and wellness company, announced today an exclusive, multi-year processing and distribution partnership with Open Book Extracts (OBX), a total solution provider for high quality cannabinoid ingredients, concept-to-market formulation services, and finished goods manufacturing for the industry's leading brands. This collaboration also marks Purissima as the first company to achieve commercial scale production of minor cannabinoids using Purissima's proprietary algae-based fermentation platform. Kicking off production in July 2022, the compounds are proposed to be available to manufacturers and sold to consumer brands before fall 2022.

Full release -

[se81] 19/7/2022 15:10

Attempt to bottom round II :)
Worth keeping an eye on RSI and the resistance in place since Dec 21

[tongosti] 14/7/2022 10:26

Resident ramper nowhere to be seen. Those who are long may consider this good news. There is a reason it makes sense to keep track of rampers in chief on these boards. Not content wise obviously as it doesn't matter at all what they say. Instead, they tend to be good proxies for crowd mood around key inflection points. Peak bearishness maybe?

[tongosti] 06/7/2022 10:10

£3.5k traded so far. Our Antigua based trillionaire building a stake maybe ...LOL

[tongosti] 03/7/2022 12:45

Love technical acronyms. As Peter Lynch used to say, there is a strong negative correlation between numbers of acronyms one employs (under the guise of "research") and the quality of their calls. This board is testament to that ain't it.

[wan] 01/7/2022 16:30

And of course it means that Quo-Test can be deployed in EKF/ADL US Labs

[wan] 01/7/2022 16:28

In the US EKF's Quo-Test is FDA 510K cleared for professional use in a clinical laboratory setting, so it will be very interesting to see if EKF's Link provides the catalyst for US sales of this analyser (and indeed increases sales across the EKF portfolio a whole).

[tongosti] 01/7/2022 15:43

70% down man - at some point we will get the inevitable bounce. Doesn't require much thinking that does it. You too have a good weekend old chap.

[wan] 01/7/2022 14:23

'On plan' news -

Industry News: EKF to highlight specific glycemic control marker at AACC 2022
EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637
30 Jun 2022

EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients.

Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material.

“The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics.

Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations.

EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely.

EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities.


Recall from the EKF Link RNS -

The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies.

Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data.

"This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities."

[tongosti] 29/6/2022 20:18

Wan - any idea why octopus fund did what they did as per latest RNS? Ta.

[tongosti] 28/6/2022 20:10

Mediocrity requires company. Here's a good evening to the 80+ crowd!

[james188] 28/6/2022 15:39

Sooty Snipes - Please just filter like the rest of us. It stops the board being clogged up with drivel.

[tongosti] 28/6/2022 15:17

Some take city managers' words as gospel. Was simply making the point that beta parades as alpha more often than not. Very relevant in this game (if you know what you're doing of course). Ta.

[sooty snipes] 28/6/2022 15:01

Jeez I'm a newcomer here at 32p but give it a rest mate. You talk more than my misses. You should change your name to Yap Yap

[tongosti] 28/6/2022 14:51

Research idea:

one goes back 3 / 5 / 10 years and compares his performance relative to SPX with the view to establish who who has bested who. passive has beaten active hands down. ah - passive is much cheaper too.

[tongosti] 28/6/2022 14:09

The fella who was equally bullish at 80+ you mean? Lol

PS. To borrow from WB - when was the last time the barber said you don’t need a haircut?

[brummy_git] 28/6/2022 14:07

Christopher Mills of Harwood Capital talks about EKF here (starts 23:15)

www.linkedin.com/posts/paul-hill-a5994116_vox-markets-fund-manager-interview-with-christopher-activity-6947490289783603200-5DnF?utm_source=linkedin_share&utm_medium=member_desktop_web

hxxps://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-interview-with-christopher-mills-3caf5ae